arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Adaptive Biotechnologies Corp

ADPT
$24.93 ▲ +1.34 (+5.68%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
36 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
28
Health
Poor
Bearish
auto_awesome

Analytical Summary

Adaptive Biotechnologies Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.9B
Dividend Yield
Revenue Growth 35.1%
Op. Margin -27.1%
ROIC -4.4%
FCF / Share $-0.07
Trailing P/E
Price / Book 18.4x
FCF Yield
Debt / Equity 0.58
info Valuation on last close. End-of-day price, Aug 7, 2026.

36-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$70.87M
↑ +35.1%
Net Income Profit after all expenses
$-20.03M
↑ +32.9%
Operating Margin Operating profit as % of sales
-27.1%
↓ -52.1% 10th
FCF / Share Free cash flow per share
$-0.07
↑ +66.7%
Long-Term Debt Long-term obligations
$124.75M
↓ -1.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
10
Returns
24
Financial Health
41
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 11 years · 36 quarters